Scantox Group
Our services support a broad spectrum of preclinical drug development elements. From lead optimization within in vitro and in vivo efficacy models, formulation development, regulatory toxicology studies incl. supportive functions as clinical pathology, bioanalysis, histology all the way to manufacturing and distribution of products for clinical trial phase 1 and 2. This enables clients to progress their development projects under one roof in a trustworthy collaborative matter based on the highest technical and scientific standards.
Our client base ranges from Start-ups, to pharmaceutical companies of all sizes, biotechs and CDMOs.
CNS/Neuropharmacology
Neurodegenerative diseases (AD/PD)
Neuropsychiatric disorders
Rare Diseases
Additional Indications
Oncology (CDx models)
Liver fibrosis
Metabolic diseases
Cross Indicational
PK/PD studies
Exploratory toxicology
Gene therapy
Immunogenicity
Analytical
Bioanalysis (GLP & GCP)
GMP Batch release testing
Dose Formulation Analysis (DFA)
Stability testing & Shelf life determination
Dissolution & Disintegration testing
Pharmaceutical Development
Preclinical Drug Formulation
Formulation Development
GMP Manufacture & Clinical Packaging Services
Analytical development & Quality Control
ICH Stability Testing
Scantox Services within the Drug Development Process
The drug and device development process timeline can be divided into different lifecycle phases, and it is often a 10+ years process for a new drug to reach the intended market.
Once a lead compound is identified within the drug discovery phase, the preclinical phase of drug development begins with in vivo research to determine the efficacy and safety of the drug. Preclinical trials test the new drug on non-human subjects for efficacy, toxicity, and pharmacokinetic (PK) information.
Scantox’ core business is studies within the Preclinical phase, but we also extend our expertise into in vitro and in vivo studies in early discovery. Scantox is catered towards providing services for both the biopharmaceutical innovative SMEs, as well as the bigger pharma companies on the global arena.
GLP Accredited Company
Scantox is your GLP-accredited CRO partner.
The fundamental purpose of the Principles of Good Laboratory Practice (GLP) is to ensure the quality and integrity of test data related to non-clinical studies. The way in which study data is generated, handled, reported, retained and archived has continued to evolve in line with the introduction and ongoing development of supporting technologies. However, the main purpose of the requirements of the Principles of GLP remains the same in having confidence in the quality, the integrity of the data and being able to reconstruct activities performed during the conduct of non-clinical studies.
Locations
Headquarters of the Scantox Group is located in Denmark, in Ejby near Køge.
Subsidiaries include:
Denmark: Ballerup
Sweden: Lund,
Gothenburg
UK: Manchester
Austria: Graz
